Antibody | Fc Variants | Binding Affinity | Effector Function | USPTO application | Status of patent | |||
---|---|---|---|---|---|---|---|---|
FcĪ³RI | FcĪ³RIIa | FcĪ³RIIIa | FcRn | |||||
Xevudy (Sotrovimab) | M428L/ N434S | N.D | ā+ā [196] | ā+ā [196] | ā+ā [205] | ā¢Enhanced ADCC ā¢Enhanced ADCP ā¢Enhanced IgG half life | 11/124,620 | Patented |
Evusheld (Cilgavimabā+āTixagevimab) | L234F/ L235E/ P331S | āāā [244] | āāā [205] | N.D | N.D | ā¢Reduced ADCC ā¢Reduced CDC ā¢Enhanced IgG half life | 16/159,451 | Patented |
M252Y/ S254T/ T256E | āāā/ā+ā [245] | āāā [245] | āāā [245] | ā+ā | 13/133,845 | Patented | ||
Etesevimab | L234A/ L235A | āāā | āāā [247] | N.D | ā+ā [205] | ā¢Reduced ADCC ā¢Reduced CDC ā¢Enhanced IgG half life | 15/210,464 | Abandoned |